Patent · US Active

Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof

US10004804B2 · kind B2 · utility

0Cited by
31References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 16, 2015
Grant dateJun 26, 2018
Priority date
Expiry dateSep 28, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/46
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.